Chongrui Xu

Yi-long Wu, Jin-Ji Yang, Chongrui Xu, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases

Jin-Ji Yang, K. Yin, Chongrui Xu, 2022, BMC Medicine.

An Autologous Therapeutic Dendritic Cell Vaccine Transfected with Total Lung Carcinoma RNA Stimulates Cytotoxic T Lymphocyte Responses Against Non-Small Cell Lung Cancer

Yi-long Wu, Chongrui Xu, S. An, 2009, Immunological investigations.

Supraclavicular lymph node incisional biopsies have no influence on the prognosis of advanced non-small cell lung cancer patients: a retrospective study

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2017, World Journal of Surgical Oncology.

Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments.

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2021, European journal of cancer.

Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer

David R. Jones, N. Schultz, M. Ladanyi, 2021, Nature Medicine.

Organ-specific efficacy in advanced non-small cell lung cancer patients treated with first-line single-agent immune checkpoint inhibitors

Chongrui Xu, Q. Gou, Hong-Hong Yan, 2022, Chinese medical journal.

Title: HER2-mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers Running title: Antitumoral activity of anti-HER2 ADCs in lung cancer

Anuja, David C. Jones, M. Berger, 2020 .

A potential treatment option for transformed small-cell lung cancer on PD-L1 inhibitor-based combination therapy improved survival.

Yi-long Wu, Jin-Ji Yang, Chao Zhang, 2022, Lung cancer.

Selective RET inhibitors shift the treatment pattern of RET fusion-positive NSCLC and improve survival outcomes

Jin-Ji Yang, Chongrui Xu, Xuchao Zhang, 2022, Journal of Cancer Research and Clinical Oncology.

Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study.

Ying Cheng, Yi-long Wu, Jin-Ji Yang, 2021, Cancer cell.

Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma

X. Yi, Yi-long Wu, W. Zhong, 2020, EBioMedicine.

EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer

Yi-long Wu, Chao Zhang, W. Zhong, 2017, Oncoimmunology.

Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non–Small Cell Lung Cancer

Yi-long Wu, Jin-Ji Yang, S. Chuai, 2017, Clinical Cancer Research.

Quantitative Radiomic Analysis for Prognostic Medical Applications

Chongrui Xu, Chongrui Xu, 2019 .

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

Yi-long Wu, Wei Li, Chongrui Xu, 2014, The Lancet. Oncology.

Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: A real-world study

Jin-Ji Yang, Chongrui Xu, Xuchao Zhang, 2023, Cell reports. Medicine.

Genetic evolution of epidermal growth factor receptor in adenocarcinoma with a bronchioloalveolar carcinoma component.

T. Mok, Yi-long Wu, Jin-Ji Yang, 2010, Clinical lung cancer.

Impact of smoking status and pathologic type on epidermal growth factor receptor mutations in lung cancer.

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2011, Chinese medical journal.

Liquid biopsy in non-small cell lung cancer: a key role in the future of personalized medicine?

Chongrui Xu, Yi-chen Zhang, Qing Zhou, 2017, Expert review of molecular diagnostics.

A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer.

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2017, Lung cancer.

Epidermal Growth Factor Receptor Mutations and Their Correlation with Gefitinib Therapy in Patients with Non-small Cell Lung Cancer: A Meta-Analysis Based on Updated Individual Patient Data from Six Medical Centers in Mainland China

T. Mok, Yi-long Wu, Wei Liu, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Complex ALK Fusions Are Associated With Better Prognosis in Advanced Non-Small Cell Lung Cancer

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2020, Frontiers in Oncology.

Effects of epidermal growth factor receptor‐tyrosine kinase inhibitors alone on EGFR‐mutant non‐small cell lung cancer with brain metastasis

Yi-long Wu, Jin-Ji Yang, Chongrui Xu, 2016, Thoracic cancer.

A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R

Yi-long Wu, Jin-Ji Yang, Chongrui Xu, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer.

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2013, Lung cancer.

The coexistence of MET over-expression and an EGFR T790M mutation is related to acquired resistance to EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2016, Oncotarget.

A randomised phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in advanced squamous cell lung carcinoma (C-TONG1002).

Ying Cheng, Yi-long Wu, Jin-Ji Yang, 2019, European journal of cancer.

The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma

Jin-Ji Yang, Yilong Wu, Chongrui Xu, 2016, Oncotarget.

Prognostic significance of genotype and number of metastatic sites in advanced non-small-cell lung cancer.

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2014, Clinical lung cancer.

A multicenter phase II study of sorafenib monotherapy in clinically selected patients with advanced lung adenocarcinoma after failure of EGFR-TKI therapy (Chinese Thoracic Oncology Group, CTONG 0805).

Ying Cheng, Yi-long Wu, Jin-Ji Yang, 2014, Lung cancer.

Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2016, Journal of Hematology & Oncology.

EGFR mutations in early‐stage and advanced‐stage lung adenocarcinoma: Analysis based on large‐scale data from China

Xing Gao, Chongrui Xu, Hong-Hong Yan, 2018, Thoracic cancer.

Intratumoral heterogeneity of EGFR-activating mutations in advanced NSCLC patients at the single-cell level

Jin-Ji Yang, Yilong Wu, Chongrui Xu, 2019, BMC Cancer.

Reduced chemotherapy sensitivity in EGFR-mutant lung cancer patient with frontline EGFR tyrosine kinase inhibitor.

Yi-long Wu, W. Zhong, Chongrui Xu, 2014, Lung cancer.

Lung Cancers with Concomitant EGFR Mutations and ALK Rearrangements: Diverse Responses to EGFR-TKI and Crizotinib in Relation to Diverse Receptors Phosphorylation

T. Mok, Yi-long Wu, Jin-Ji Yang, 2014, Clinical Cancer Research.

Can EGFR-TKIs be used in first line treatment for advanced non-small cell lung cancer based on selection according to clinical factors ? -- A literature-based meta-analysis

Yi-long Wu, Chongrui Xu, Qing Zhou, 2012, Journal of Hematology & Oncology.

P1.01-018 Acquired Resistance to Crizotinib in Advanced NSCLC with De Novo MET Overexpression

Jin-Ji Yang, W. Zhong, Z. Xie, 2017 .

Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non–small-cell Lung Cancer

Yi-long Wu, Wei Li, Chongrui Xu, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions.

David R. Jones, M. Berger, C. Rudin, 2021, Lung cancer.

Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial

Yi-long Wu, Jin-Ji Yang, Chongrui Xu, 2019, EBioMedicine.

Lung cancer treatment disparities in China: a question in need of an answer.

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2014, The oncologist.

Detection of Driver and Resistance Mutations in Leptomeningeal Metastases of NSCLC by Next-Generation Sequencing of Cerebrospinal Fluid Circulating Tumor Cells

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2017, Clinical Cancer Research.

Integrative nomogram of CT imaging, clinical, and hematological features for survival prediction of patients with locally advanced non-small cell lung cancer

Bowen Xin, Dagan Feng, Huaqi Zhang, 2019, European Radiology.

Is 18F-fluorodeoxyglucose positron emission tomography-based metabolic response superior to Response Evaluation Criteria In Solid Tumors-based response after two cycles of platinum-based chemotherapy in predicting clinical outcome of untreated patients with advanced non-small cell lung cancer?

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2011, Nuclear medicine communications.

Feasibility of computed tomography‐guided core needle biopsy in producing state‐of‐the‐art clinical management in Chinese lung cancer

Yi-long Wu, Jin-Ji Yang, Chongrui Xu, 2014, Thoracic cancer.

EGFR/KRAS Mutations and Gefitinib Therapy in Chinese NSCLC Patients

Chongrui Xu, Qing Zhou, Zhen Wang, 2008, Oncology Research and Treatment.

Docetaxel as salvage chemotherapy in patients with advanced non-small cell lung cancer after failure of cytotoxic agents and gefitinib treatment

Yi-long Wu, Jin-Ji Yang, Chongrui Xu, 2008 .

Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations

Yi-long Wu, Jin-Ji Yang, W. Zhong, 2016, Oncotarget.

Circulating tumor DNA (ctDNA)-based minimal residual disease in non-small cell lung cancer

Ruiyang Li, Chongrui Xu, Qing Zhou, 2023, Chinese Medical Journal Pulmonary and Critical Care Medicine.

Genomic Characterization of ERBB2-Driven Biliary Cancer and a Case of Response to Ado-Trastuzumab Emtansine.

M. Berger, D. Solit, G. Abou-Alfa, 2019, JCO precision oncology.

Principles of biopsy in suspected lung cancer: priority still based on invasion in the era of targeted therapy?

Yi-long Wu, Jin-Ji Yang, Chongrui Xu, 2013, Journal of thoracic disease.

First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial

Yangqiu Li, Jin-Ji Yang, Chongrui Xu, 2023, Nature Network Boston.

A phase II trial comparing pemetrexed with gefitinib as the second-line treatment of nonsquamous NSCLC patients with wild-type EGFR (CTONG0806).

Ying Cheng, Yi-long Wu, Jin-Ji Yang, 2013 .

Intratumoral heterogeneity of EGFR-activating mutations in advanced NSCLC patients at the single-cell level

Jin-Ji Yang, Yilong Wu, Chongrui Xu, 2019, BMC Cancer.

The spatiotemporal evolution of EGFR C797S mutation in EGFR-mutant non-small cell lung cancer: opportunities for third-generation EGFR inhibitors re-challenge.

Yi-long Wu, Jin-Ji Yang, Chongrui Xu, 2019, Science bulletin.

Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial.

Yi-long Wu, W. Feng, W. Zhong, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Effectiveness and safety of camrelizumab in inoperable or advanced non-small cell lung cancer patients: a multicenter real-world retrospective observational study (CTONG2004-ADV)

Yi-long Wu, Chongrui Xu, L. Sheng, 2023, Translational lung cancer research.

A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations

Yi-long Wu, Xue-Ning Yang, W. Zhong, 2017, British Journal of Cancer.

[Relationship of the curative effects of gefitinib on non-small cell lung carcinoma to gender and to epithelial growth factor receptor status].

Yi-long Wu, Jin-Ji Yang, Xue-Ning Yang, 2006, Zhonghua yi xue za zhi.

Yi-long Wu, Wei Li, Chongrui Xu, 2014, The Lancet. Oncology.

Immune suppressive microenvironment in liver metastases contributes to organ-specific response of immunotherapy in advanced non-small cell lung cancer

Chongrui Xu, Q. Gou, Hong-Hong Yan, 2023, Journal for ImmunoTherapy of Cancer.

Genomic and immune characteristics of HER2‐mutated non‐small‐cell lung cancer and response to immune checkpoint inhibitor‐based therapy

Jin-Ji Yang, W. Zhong, K. Yin, 2023, Molecular oncology.

Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer

David R. Jones, N. Schultz, M. Ladanyi, 2022, Nature Medicine.

Dynamic circulating tumor DNA during chemoradiotherapy predicts clinical outcomes for locally advanced non-small cell lung cancer patients.

Jin-Ji Yang, Xue-Ning Yang, W. Zhong, 2023, Cancer cell.

Redoxhigh phenotype mediated by KEAP1/STK11/SMARCA4/NRF2 mutations diminishes tissue-resident memory CD8+ T cells and attenuates the efficacy of immunotherapy in lung adenocarcinoma

Jin-Ji Yang, Chongrui Xu, Xuchao Zhang, 2024, Oncoimmunology.

Identification of a risk score model based on tertiary lymphoid structure‐related genes for predicting immunotherapy efficacy in non‐small cell lung cancer

Chongrui Xu, Zhi-hong Chen, Jia-Qi Liu, 2024, Thoracic cancer.

Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104)

Xue-Ning Yang, Chongrui Xu, Li-xu Yan, 2024, Cell reports. Medicine.

Efficacy, safety and dose selection of AZD3759 in patients with untreated EGFR-mutated non-small-cell lung cancer and central nervous system metastases in China (CTONG1702-Arm 8): a multi-center, single-arm, phase 2 trial

Yi-long Wu, Jin-Ji Yang, Chongrui Xu, 2023, EClinicalMedicine.

Phase I/Ib dose-escalation study of avelumab in Chinese patients with advanced solid tumors.

Y. Liu, Wei Wang, Y. Xin, 2022, Future oncology.

PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trial.

Jin-Ji Yang, Chongrui Xu, Xuchao Zhang, 2023, Science bulletin.

Plasma ddPCR for the detection of MET amplification in advanced NSCLC patients: a comparative real-world study

Jin-Ji Yang, Chongrui Xu, Xuchao Zhang, 2024, Therapeutic advances in medical oncology.